Genetics

Gene Therapy Treatments Are Filling Some Companies’ Pipelines

Gene Therapy Treatments Are Filling Some Companies’ Pipelines

Major pharma companies in ophthalmology aren’t the only ones making plays in the gene therapy space, as we reported last week. Mid-size and small companies are also making moves, as evidenced by Astellas Pharma’s acquisition last week of Quethera, which is pursuing a novel gene therapy program for treatment of glaucoma. This week, we look…

Read More

Big Companies Keep Making Big Plays in Gene Therapy

Big Companies Keep Making Big Plays in Gene Therapy

When Allergan and Editas Medicine disclosed this week that they would move forward on their collaboration to develop a genome editing-medicine for treatment of an inherited retinal disorder, it was the latest move into genetic medicine by big ophthalmology players. Already, Novartis had made two significant moves in the gene therapy space, and Roche expanded…

Read More

Eye Care Plays Big at Gene and Cell Meeting

Eye Care Plays Big at Gene and Cell Meeting

Eye care commanded a key stage at the 21st Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) last week in Chicago. In all, 53 abstracts in retina were presented, but there were also presentations in glaucoma, corneal clouding, and even an ocular muscular disorder. Here are four presentations by companies in…

Read More

15 Things We Learned at OIS@ASCRS

Takeaways from OIS@ASCRS 2018

Here are 15 takeaways from last week’s OIS@ASCRS 2018. Barry Cheskin of PowerVision reported on a pilot study of 27 patients who had the FluidVision accommodating intraocular lens implanted. The average objective accommodation at six months measured 2.00 diopters, he said. For the first time, Keranova presented preclinical results of its all-in-one cataract surgery platform.…

Read More

41 Things On Tap at OIS@ASCRS

41 Things On Tap at OIS@ASCRS

There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 – including five different breakout sessions on everything from dry eye to emerging glaucoma therapies, the signature sessions on public market activity and “Masters of the Industry,” and a new panel on frontiers in femtosecond lasers. It’s all set for next Thursday, April…

Read More

MeiraGTx Gene Therapy Candidate for Achromatopsia Moves Forward

Emerging Gene Therapy Candidate Advances

An emerging gene therapy candidate for the treatment of inherited eye disease has taken a step forward with MeiraGTx announcing that it has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for A002, which is for the treatment of achromatopsia (ACHM) due to mutations in the CNGB3 gene. A few weeks earlier,…

Read More

Handicapping the Entries in the Geographic Atrophy Space

Handicapping the Entries in the Geographic Atrophy Space

The race to find an effective treatment for geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD) for which no approved treatment exists, has zeroed in on the complement pathway – and among the three lead candidates in this space, Apellis Pharmaceuticals’ APL-2 seems to have the early lead. Another lead contender, Ophthotech’s…

Read More

Can Ocular Therapies Diversify Biogen Portfolio?

Can Ocular Therapies Diversify Biogen Portfolio? - Eye On Innovation Article - Healthegy

Biotechnology company Biogen (Cambridge, MA) recently committed $20 million into a collaboration with the University of Pennsylvania to co-develop gene therapies using next-generation adeno-associated virus (AAV) gene delivery vectors, which have shown promise in early studies for treating a variety of retinal disorders. Biogen seems to be moving quickly into the ocular gene therapy arena.…

Read More

Eye on Five – February Edition

OIS - Eye on Five

The Transcend acquisition tops the list, but February was a promising month for ophthalmology. Alcon Leaps into MIGS with Transcend With its acquisition of Transcend Medical and its CyPass Micro-Stent platform for glaucoma, Novartis aims to kick start the lackluster growth of its Alcon unit by tapping into the high-growth micro-invasive glaucoma surgery device market…

Read More

Avalanche’s Post-AMD Pivot Takes Step Outside Ophthalmology

Avalanche’s Post-AMD Pivot Takes Step Outside Ophthalmology - OIS Article

How far will Avalanche Biotechnologies Inc.’s pivot take it outside of ophthalmology? Following the release of disappointing topline results of its lead gene therapy candidate for age-related macular degeneration last June, Avalanche Biotechnologies has undertaken a series of significant pivots to right its ship. After releasing those results, the Menlo Park, CA, biotech company underwent…

Read More

Gene Therapies Move One Step Closer to Reality

Gene Therapies Move One Step Closer to Reality

Positive top-line results from a pivotal Phase III study may result in the first gene therapy to win U.S. regulatory approval, and sent shares of the developer skyrocketing. Earlier this week, Spark Therapeutics (Philadelphia) announced its lead candidate, SPK-RPE65, was able to improve functional vision in patients with a rare form of a genetic disorder…

Read More